Blood gene expression signatures associate with heart failure outcomes.
Gene expression signatures in blood correlate with specific diseases. Such signatures may serve as valuable diagnostic and prognostic tools in disease management. Blood gene expression signatures associated with heart failure may be applied to predict prognosis, monitor disease progression, and optimize treatment. Blood gene expression profiles were generated for 71 subjects with heart failure and 15 controls without heart failure, using the Affymetrix GeneChip U133Plus2.0. Survival analysis identified 197 "mortality genes" that were significantly associated with patient outcome. Functional categorization showed that genes associated with T cell receptor signaling were most significantly overpresented. Cluster analysis of these T cell receptor signaling genes significantly categorized heart failure patients into three risk groups (P = 0.031) that were distinct from the three risk groups categorized by New York Heart Association (NYHA) Classification (P = 0.0002). By combining the analysis of clinical assessment (NYHA class) with T cell receptor signaling gene expression, we proposed a model that demonstrated an even greater differentiation of patients at risk (P = 0.0001). In this discovery study, we identified blood expression signatures associated with heart failure patient outcomes. Characterization of these mortality genes helped identify a set of T cell receptor signaling genes that may be of utility in predicting survival of heart failure patients. These data raise the possibility of prospectively risk stratifying patients with heart failure by integrating blood gene expression signatures with current clinical assessment.
Department of Medicine, Cardiology Unit, University of Vermont, Burlington, Vermont, USA. peter.vanburen@uvm.edu
Peter
P
Vanburen
Jun
J
Ma
Samuel
S
Chao
Enkhtuyaa
E
Mueller
David J
DJ
Schneider
Choong-Chin
CC
Liew
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016000:Cluster Analysis; D018450:Disease Progression; D020869:Gene Expression Profiling / Q000379:methods*; D006333:Heart Failure / Q000097:blood / Q000235:genetics* / Q000401:mortality*; D006801:Humans; D046228:Microarray Analysis / Q000379:methods*; D008875:Middle Aged; D011379:Prognosis; D011948:Receptors, Antigen, T-Cell / Q000032:analysis* / Q000097:blood; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
D011948:Receptors, Antigen, T-Cell
Circulation. 1998 Jul 14;98(2):149-56
9679721
Physiol Genomics. 2005 May 11;21(3):299-307
15769906
Circulation. 2000 Nov 14;102(20 Suppl 4):IV14-23
11080127
Am J Pathol. 2005 Aug;167(2):305-13
16049318
Circulation. 1998 Jan 6-13;97(1):19-22
9443426
Cardiol Clin. 1998 Nov;16(4):645-56, viii
9891594
N Engl J Med. 2008 May 15;358(20):2148-59
18480207
JAMA. 2004 Jul 21;292(3):344-50
15265849
Int J Cardiol. 2006 May 10;109(2):179-87
16024109
Physiol Genomics. 2001 Jun 06;6(1):19-28
11395543
J Mol Cell Cardiol. 2003 Aug;35(8):993-8
12878486
Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9440-5
12883005
Am J Cardiol. 2005 Jun 6;95(11A):9C-16C; discussion 38C-40C
15925559
Atherosclerosis. 2007 Mar;191(1):63-72
16806233
Circulation. 2005 May 31;111(21):2837-49
15927992
Am J Cardiol. 1999 Feb 1;83(3):376-82
10072227
N Engl J Med. 2002 Jul 18;347(3):161-7
12124404
JAMA. 2009 Jan 28;301(4):383-92
19176440
J Am Coll Cardiol. 2009 May 12;53(19):1752-9
19422981